微生物组感知药物开发的新兴工具和技术。

IF 5.5 2区医学 Q1 PHARMACOLOGY & PHARMACY

Clinical Pharmacology & Therapeutics Pub Date : 2025-08-11 DOI:10.1002/cpt.70026

Henry J Haiser, David de Gruijl

引用次数: 0

摘要

药物组微生物学探索肠道微生物群在药代动力学和药效学中的作用，为新的生物标志物和干预策略铺平道路，以减少药物反应的个体差异。新兴的机制见解和工具使微生物组感知方法成为个性化医疗的一个有前途的新方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Emerging Tools and Technologies for Microbiome-Aware Drug Development.

Pharmacomicrobiomics explores the role of the gut microbiota in pharmacokinetics and pharmacodynamics, paving the way for new biomarkers and intervention strategies to reduce interindividual variability in drug response. Emerging mechanistic insights and tools enable microbiome-aware approaches as a promising new facet of personalized medicine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Pharmacology & Therapeutics 医学-药学

CiteScore

12.70

自引率

7.50%

发文量

290

审稿时长

2 months

期刊介绍： Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.